Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Arimi Ueda"'
Autor:
Yuki Ogawa, Katsuhiko Nagase, Arimi Ueda, Momoko Yamada, Mai Okano, Tsutomu Shimada, Yoshimichi Sai
Publikováno v:
Drug Metabolism and Pharmacokinetics. 35:534-538
Erlotinib shows pH-dependent solubility and its absorption is decreased in patients receiving gastric acid suppression therapy. Here, we examined whether administration of erlotinib in acidic solutions would improve its solubility and absorption char
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c10d9f224150c964d8cfd07d5c32d91b
https://doi.org/10.1016/j.dmpk.2020.08.003
https://doi.org/10.1016/j.dmpk.2020.08.003
Autor:
Kenshi Suzuki, Yutaka Hattori, Tadao Ishida, Tomomi Takei, Maiko Matsushita, Daiju Ichikawa, Arimi Ueda, Nobuhiro Tsukada, Tomofumi Yamamoto, Masahiro Ikeda
Publikováno v:
Blood. 128:5620-5620
Background & Objective The therapy of multiple myeloma (MM) has improved greatly over the last decade. However, the rise in health care costs has become a big problem. Therefore, it is necessary to consider the cost-effectiveness including Quality of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::04c9ac928b82deda6cbfb716ee796cd3
https://doi.org/10.1182/blood.v128.22.5620.5620
https://doi.org/10.1182/blood.v128.22.5620.5620
Autor:
Arimi Ueda, Shotaro Kitabatake, Eriko Kamiyama, Takashi Yamaguchi, Maiko Matsushita, Daiju Ichikawa, Noriko Tabata, Masashi Hozumi, Yutaka Hattori, Mariko Sato, Hiroshi Yanagawa
Publikováno v:
Blood. 126:1800-1800
PURPOSE: Recent progress of the treatment of multiple myeloma (MM) has significantly improved prognosis. However, the MM patients with high-risk cytogenetic abnormalities still showed significantly shorter survival. The purpose of this study is to fi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70c373378b142043ac5975e9b9b891f4
https://doi.org/10.1182/blood.v126.23.1800.1800
https://doi.org/10.1182/blood.v126.23.1800.1800
Autor:
Masashi Hozumi, Shotaro Kitabatake, Hiroshi Yanagawa, Noriko Tabata, Maiko Matsushita, Daiju Ichikawa, Yutaka Hattori, Arimi Ueda, Hirokazu Shiheido
Publikováno v:
Blood. 124:5718-5718
BACKGROUND: Despite recent advances in the use of newly developed drugs including immune-modulatory drugs (IMiDs) such as thalidomide, lenalidomide, and pomalidomide and proteasome inhibitors such as bortezomib, carfilzomib, and MLN9708, MM is still
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cbbd2e0c634799ade5f63debc8032e9a
https://doi.org/10.1182/blood.v124.21.5718.5718
https://doi.org/10.1182/blood.v124.21.5718.5718